Cantor Fitzgerald Weighs in on Legend Biotech FY2026 Earnings

Legend Biotech Co. (NASDAQ:LEGN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Legend Biotech in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski anticipates that the company will post earnings per share of $0.24 for the year. Cantor Fitzgerald has a "Overweight" rating and a $55.00 price target on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.33. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm had revenue of $195.05 million for the quarter, compared to analysts' expectations of $190.83 million. During the same quarter last year, the company posted ($0.16) EPS. The business's quarterly revenue was up 107.8% on a year-over-year basis.

A number of other research firms have also recently issued reports on LEGN. Royal Bank of Canada reiterated an "outperform" rating and issued a $84.00 price objective on shares of Legend Biotech in a report on Tuesday, April 22nd. HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of Legend Biotech in a research report on Wednesday, April 16th. Truist Financial cut their target price on Legend Biotech from $88.00 to $71.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Morgan Stanley decreased their price target on shares of Legend Biotech from $82.00 to $80.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Legend Biotech in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $76.20.

Legend Biotech Price Performance

LEGN traded down $1.08 during trading on Tuesday, reaching $36.83. The stock had a trading volume of 1,553,091 shares, compared to its average volume of 1,334,053. The business has a 50-day moving average of $31.96 and a 200-day moving average of $34.49. Legend Biotech has a one year low of $27.34 and a one year high of $60.87. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.90 and a current ratio of 4.98. The stock has a market cap of $6.77 billion, a PE ratio of -38.77 and a beta of 0.13.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Legend Biotech by 145.4% in the 1st quarter. GAMMA Investing LLC now owns 1,291 shares of the company's stock worth $44,000 after acquiring an additional 765 shares during the last quarter. Quarry LP bought a new stake in shares of Legend Biotech in the first quarter worth about $48,000. GF Fund Management CO. LTD. purchased a new position in Legend Biotech during the 4th quarter valued at about $56,000. Brooklyn Investment Group increased its holdings in Legend Biotech by 1,114.8% during the 1st quarter. Brooklyn Investment Group now owns 1,725 shares of the company's stock valued at $59,000 after purchasing an additional 1,583 shares during the period. Finally, Signaturefd LLC raised its position in Legend Biotech by 1,052.7% during the 4th quarter. Signaturefd LLC now owns 1,729 shares of the company's stock valued at $56,000 after purchasing an additional 1,579 shares during the last quarter. Institutional investors own 70.89% of the company's stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).